1. Introduction
===============

Pertussis or whooping cough is a disease that has been increasing in prevalence in the United States (US) over the last 25 years.^\[[@R1]--[@R4]\]^ From 2010 through 2013, there were over 123,000 cases of pertussis documented in the US.^\[[@R4]--[@R7]\]^ While the primary etiologic agent of whooping cough has been considered to be *Bordetella pertussis*, a similar illness can be caused by *Bordetella parapertussis*.^\[[@R3]\]^*B. parapertussis* is generally considered to cause disease with milder symptoms; however, children with *B. parapertussis* infection can present with typical whooping cough symptoms, including prolonged cough, paroxysms, whooping, and posttussive vomiting.^\[[@R3],[@R8]--[@R10]\]^ As interest in whooping cough has grown, it has become apparent that *B. parapertussis* is more prevalent than previously assumed and that it may be contributing to the overall pertussis burden.^\[[@R8],[@R10],[@R11]\]^

While vaccination against pertussis has become ubiquitous in most developed countries using acellular (as in the US) or whole-cell *B. pertussis* vaccines, it has become increasingly clear that neither provides protection against *B. parapertussis*.^\[[@R9]--[@R13]\]^ This may be in part due to the fact that the vaccines currently contain antigens from *B. pertussis* only,^\[[@R12]\]^ and that *B. parapertussis* can evade human immune responses^\[[@R14]--[@R19]\]^; paradoxically, *B. pertussis* vaccine itself may increase host susceptibility to *B. parapertussis*.^\[[@R12],[@R20]\]^

Little is known about the epidemiology of *B. parapertussis*. It has been suggested to have a 4-year cycle,^\[[@R21]\]^ with no seasonality^\[[@R8]\]^; however, it appears that outbreaks can occur.

Reports of outbreaks of *B. parapertussis* have increased in the recent literature. In 2010, an outbreak of 3 *Bordetella* species---*B. pertussis, B. parapertussis*, and *B. holmesii*---was reported, in which clinical features at presentation did not allow for clear differentiation of etiology.^\[[@R22]\]^ In the winter months of 2011 to 2012, an outbreak of *B. parapertussis* with pertussis-like illness occurred in Wisconsin.^\[[@R23]\]^ Reports of *B. parapertussis* have increased not just in the US, but also globally,^\[[@R24]--[@R27]\]^ with *B. parapertussis* now being the dominant species in Europe and the Middle East.^\[[@R24],[@R25],[@R28]\]^

Overall, it has become apparent that, while mass vaccination campaigns have existed globally for over 50 years, the incidence of pertussis/whooping cough is increasing in developed countries and remains a problem of clinical significance. This is a result of not just *B. pertussis*, but also *B. parapertussis*. The objective of the present study was to describe an outbreak of *B. parapertussis* in 2014 in Minnesota; as shown by the data presented, other parts of the US were likely affected.

2. Materials and methods
========================

2.1. Design
-----------

The Mayo Clinic Institutional Review Board approved this study. The study was a retrospective cohort study of patients who tested positive for *B. parapertussis*.

2.2. Study population
---------------------

Mayo Clinic Rochester is the primary provider of healthcare for a large area of Southeastern Minnesota. Mayo Medical Laboratories is a reference laboratory that tests patients from around the country. To examine whether the outbreak witnessed in Southeast Minnesota was a localized event, or an event extending beyond Southeastern Minnesota, reference laboratory data were examined. All patients, from Southeastern Minnesota and nationally, who tested positive or negative for *B. parapertussis* by polymerase chain reaction (PCR) performed on nasopharyngeal specimens from December 2011 through December 2014 were identified. Parapertussis cases were defined as patients with PCR positive for *B. parapertussis*. For patients who tested positive for *B. parapertussis* between January and December 2014 in Southeastern Minnesota, the electronic medical records were reviewed for demographics, symptomology, medical history, and vaccination history (Minnesota Statute 144.335). For the national patients, information was collected as to date and location of nasopharyngeal collection for both positives and negatives from December 2011 through December 2014.

2.3. PCR for *B. parapertussis*
-------------------------------

Nasopharyngeal swabs were submitted by healthcare provider request for *B. pertussis/B. parapertussis* PCR. Nasopharyngeal swab samples were placed into tubes with neutralization buffer and subjected to heat lysis on a Thermomixer R (Eppendorf AG; Hamburg, Germany) for 6 minutes at 99 °C and 1400 rpm, followed by centrifugation for 20 seconds at 20,800 × *g*. Then, 5 μL of the supernatant was combined with 15 μL of PCR master mix and tested using a previously described duplex PCR assay targeting IS*481* and IS*1001* for *B. pertussis* and *B. parapertussis* detection, respectively.^\[[@R29]\]^

2.4. Medical record review and analysis for Southeast Minnesota
---------------------------------------------------------------

Electronic medical records of the study population from Mayo Clinic Rochester were reviewed for the following variables: age at onset of disease, date of birth, sex, duration of symptoms before presentation to a healthcare professional, report of any contact with pertussis, documented cough symptoms (and whether the cough was productive or not), nasal symptoms (coryza, rhinorrhea, or congestion), sore throat, fever, posttussive emesis, and apnea. Information on related medical history was also recorded, including history of asthma, chronic obstructive pulmonary disease, and tobacco exposure. Dates of pertussis vaccine administration and whether a patient was "up-to-date" with pertussis vaccine (i.e., had received the correct number of pertussis vaccinations as suggested by the Centers for Disease Control and Prevention \[CDC\]) were recorded. Information on treatment was collected, including pharmacological treatment by healthcare personnel, recurrence of symptoms resulting in another visit within 6 months and prior visits with a missed diagnosis.

2.5. Statistical analyses
-------------------------

Means and percentages were calculated for demographic and descriptive data in patients from Mayo Clinic Rochester. The percent positive rate was calculated at the national level and in Southeastern Minnesota. The national data were further divided into 10 regions based on geographic groupings used by the US Department of Health and Human Services and (for influenza surveillance) by the CDC as follows:1.Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, and Vermont2.New Jersey and New York3.Delaware, District of Columbia, Maryland, Pennsylvania, Virginia, and West Virginia4.Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, and Tennessee5.Illinois, Indiana, Michigan, Ohio, and Wisconsin6.Minnesota only7.Arkansas, Louisiana, New Mexico, Oklahoma, and Texas8.Iowa, Kansas, Missouri, and Nebraska9.Colorado, Montana, North Dakota, South Dakota, Utah, and Wyoming10.Arizona, California, Hawaii, and Nevada11.Alaska, Idaho, Oregon, and Washington.

CDC region 5 was divided into solely Minnesota (5′) and the rest of region 5 (5) to prevent skewing of region 5 data by Minnesota, as approximately 60% of samples from region 5 were from Minnesota. The percent positivity, mean, number of total tests performed, and confidence interval were displayed graphically.

3. Results
==========

The percent positivity of nasopharyngeal specimens for *B. parapertussis* in Southeastern Minnesota is shown in Fig. [1](#F1){ref-type="fig"}. In 2012, there were a total of 23 patients who tested positive for *B. parapertussis* and in 2013, a total of 2 patients. Thirty-one patients tested positive for *B. parapertussis* in 2014; of these, 81% (25) tested positive from October through December.
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Of the 31 positive patients in 2014, 25 consented to have their records reviewed (Minnesota Statute 144.335). Patient age ranged from less than 1 to 11 years (mean 5.9 years), and 14 (56%) were male. Five patients reported "exposure to pertussis." Four reported a family member with "pertussis." Two pairs of siblings were affected. Patients presented for medical evaluation with an average duration of symptoms of 2.6 weeks before testing. All reported cough as their primary symptom. Ten (40%) reported posttussive vomiting, 10 (40%) coryza, 8 (32%) apnea/sleep disturbance, and 3 (12%) sore throat. At the time of examination, all patients were afebrile.

Twenty-two of 25 patients were prescribed azithromycin. Three were not given antibiotic therapy, as they were considered as being past the antibiotic treatment window.

Seven were diagnosed or treated for another disease or condition considered to be causing their cough before the visit with nasopharyngeal swab confirmation of *B. parapertussis*. These conditions included croup, "chronic cough," bronchitis, "post-viral cough," "cough NOS," and exacerbated asthma. In these cases, treatment included dexamethasone, amoxicillin, albuterol, and/or steroids. Three patients had medical appointments for continued respiratory/cough symptoms in the 6 months following *B. parapertussis* diagnosis; 1 was evaluated for an upper respiratory tract infection 2 months after diagnosis, 1 was evaluated for an upper respiratory tract infection 1 and 4 months after diagnosis, and 1 was evaluated for "cough" at 3 and 4 months following *B. parapertussis* diagnosis (due to continued symptoms). Overall however, patients improved and symptoms resolved. All patients were "up to date" with pertussis vaccination as recommended by the CDC.

The percent positivity for *B. parapertussis* on a national scale (using reference laboratory data) is shown in Fig. [2](#F2){ref-type="fig"}. From December 2011 through December 2014, 120,113 patients were tested via PCR for *B. parapertussis*, of which 1098 were positive. An increase in percent positivity was observed starting in July 2014 and continued through December 2014. Figure [3](#F3){ref-type="fig"} shows the national reference laboratory data by geographic region. There was a sizeable increase in the percent positivity in regions 1, 2, 3, 5, 5′, and 7. Comparing the percent positivity from April through December 2014 between regions, regions 8, 9, and 10 were not significantly different from each other but were significantly different (*P* \< .05) from all other regions, except region 4. This further suggests that they did not experience the same increased incidence as the other regions.

![Percent positivity of the *B. parapertussis* polymerase chain reaction assay nationally using Mayo Medical Laboratories reference laboratory data (December 2011--2014).](medi-96-e6730-g002){#F2}
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4. Discussion
=============

There was an outbreak of *B. parapertussis* in Southeastern Minnesota in late 2014. As shown in Fig. [1](#F1){ref-type="fig"}, there was an increase in cases in the months of October through December of 2014. In addition, the increased percent positivity from regions 1, 2, 3, 5, 5′, and 7 suggests that this outbreak was not unique to Southeastern Minnesota but extended to the Northeast and Midwest US, while sparing the Southwest and West Coast.

While originally considered as a cause of less severe whooping cough, it is becoming increasingly accepted that *B. parapertussis* can cause typical pertussis symptomology. In the present study, symptoms were similar to those expected with *B. pertussis*. This is consistent with recent literature suggesting that *B. parapertussis* infection presents as typical whooping cough.^\[[@R3],[@R8]--[@R10]\]^ This suggests that symptoms alone should not be used to make a distinction between *B. pertussis* and *B. parapertussis*. More importantly, it supports testing for both *B. pertussis* and *B. parapertussis* together in patients with whooping cough symptomatology.

It should also be noted that all patients in Southeastern Minnesota with *B. parapertussis* were vaccinated against pertussis, suggesting that pertussis vaccination is ineffective against *B. parapertussi*s, consistent with most of the recent literature.^\[[@R11]--[@R13],[@R17],[@R20]\]^ Redevelopment of the pertussis vaccination has become a topic of considerable discussion, with new approaches being studied.^\[[@R30],[@R31]\]^ Our findings suggest that *B. parapertussis* should be considered when developing new pertussis vaccines. Also of note is that the average age of patients with *B. parapertussis* was much younger than those with *B. pertussis*. During a 2012 *B. pertussis* outbreak in a similar population in Southeastern Minnesota, we found that the average age of patients with *B. pertussis* was 15.6 years.^\[[@R32]\]^ This contrasts with the mean age in the present study population which was 5.9 years, underscoring the lack of activity of the current vaccination strategy against *B. parapertussis*.

This and other recent studies highlight the importance of *B. parapertussis* surveillance, and possibly surveillance for other related species, as causes of cough illness. Unlike *B. pertussis*, *B. parapertussis* is not considered a nationally notifiable disease by the Nationally Notifiable Disease Surveillance System of the CDC. Only a positive test for *B. pertussis* (PCR or isolation from clinical specimen) is considered a criterion for diagnosis of pertussis. The data presented herein suggest that *B. parapertussis* should be considered for inclusion in this definition.

An accepted practice for passive detection of *B. pertussis* is to actively search for and notify potential cases (e.g., household, family, daycare, healthcare workers, and other close contacts). This can lead to a significant increase in detection.^\[[@R33]\]^ The recent literature, as well as the present study findings that siblings were positive for *B. parapertussis* together and that infected symptomatic patients reported "prior exposure to pertussis," suggests that it might be beneficial to formally adopt a similar strategy for *B. parapertussis*.

The findings of several studies suggest that *B. parapertussis* may be increasing in the US and globally; besides the *B. parapertussis* outbreak described here, increased detection and other *B. parapertussis* outbreaks have been described.^\[[@R22]--[@R28]\]^ A possible explanation for these observations may be selective pressures exerted on *Bordetella* species, especially given that current pertussis vaccines are likely ineffective against *B. parapertussis*. It is also possible that surveillance and detection have improved, through improved diagnostics, and specifically, inclusion of *B. parapertussis* in some assays used for pertussis testing of nasopharyngeal specimens.

It is important to note that all data presented in the present study are based on PCR only, without culture. While PCR provides excellent sensitivity, culture may be more definitive due to its specificity.^\[[@R34]\]^ Another possible limitation of the study is that not everyone seeks medical attention for testing. In particular, it is possible that less severe parapertussis infections may have been left unidentified. It is also important to note that healthcare providers' practices of testing for *B. parapertussis* can be variable and influenced by the presence of recent positive testing. Another limitation lies in the fact that our findings are retrospective and observational. Specific to the Mayo Clinic Rochester study population, the catchment area for the Mayo Clinic is small, extending predominantly into Southeastern Minnesota. This and the small sample size limit our ability to make generalized inferences. For the Mayo Medical Laboratories data, it is important to note that certain regions of country, especially some West Coast states, and Hawaii and Alaska, are less represented than others.

In conclusion, in 2014, there was an outbreak of *B. parapertussis* in Southeastern Minnesota and likely other parts of the US. Symptoms were similar to those expected with *B. pertussis*. All patients had been vaccinated against pertussis. Results of this study demonstrate that *B. parapertussis* can cause a cough illness comparable to that caused by *B. pertussis* and that it is not prevented by pertussis vaccination.

This work was presented in part at the 55th Interscience Conference of Antimicrobial Agents and Chemotherapy, San Diego, CA, 2015.

Abbreviations: *B. parapertussis* = *Bordetella parapertussis*, *B. pertussis* = *Bordetella pertussis*, CDC = Centers for Disease Control and Prevention, PCR = Polymerase Chain Reaction.

RP has a patent on *Bordetella pertussis/parapertussis* PCR. VPK received an Infectious Disease Society of America 2016 Medical Scholar scholarship to perform the research presented.

Presented in part at the 55th Interscience Conference of Antimicrobial Agents and Chemotherapy, San Diego, CA, 2015.

The authors have no funding and conflicts of interest to disclose.
